Drug Profile
Research programme: AAV-based gene therapeutics - Aevitas Therapeutics
Alternative Names: AVTS-001Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Aevitas Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration; Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 11 Apr 2024 AAV-based gene therapeutics is still in preclinical development for Haemolytic-uraemic-syndrome, Paroxysmal-nocturnal-haemoglobinuria, Age-related-macular-degeneration in USA (Fortress Biotech Pipeline, April 2024)
- 24 Apr 2023 4D Molecular Therapeutics acquires payload from Aevitas Therapeutics
- 28 Aug 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA